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Clinical background
Despite recent advances, the prognosis for patients with
pulmonary hypertension remains poor. Riociguat (BAY
63-2521) is a novel oral stimulator of the nitric oxide
(NO) receptor soluble guanylate cyclase, and synergizes
with low levels of bioavailable NO. Its safety and efficacy
in dose titration were studied in patients with PAH (n =
33) or CTEPH (n = 42) in this multicenter open-label
uncontrolled phase 2 trial.
Results
Patients received riociguat tid for 12 weeks. Doses were
titrated according to systolic blood pressure (SBP) and tol-
erability; 3 7.5 mg/day was generally well tolerated. Hypo-
tension (SBP < 90 mmHg) occurred in 11 cases, but SBP
often normalized without dose alteration (n = 9); in 2
cases a reduced dose was well tolerated.
Mean pulmonary arterial pressure (PAP) and pulmonary
vascular resistance (PVR) decreased from baseline (PAP,
5.3 mmHg; PVR, 253 dyn.s/cm5; p < 0.0001), and cardiac
output increased (0.88 L/min; p < 0.0001). Slight changes
from baseline were seen in mean SBP (124 -> 117 mmHg)
and heart rate (77 -> 80 bpm). PVR/systemic vascular
resistance ratio showed slight pulmonary selectivity (p =
0.0064). Tei index, systolic PAP and TAPSE showed
improvement (p 0.0041). Mean 6-minute walking dis-
tance (6MWD) increased in patients with PAH (+73.5 m;
p < 0.0001) or CTEPH (+64.3 m; p < 0.0001), and similar
trends were found in 6 bosentan-pretreated patients. Sim-
ilar increases were seen in patients in WHO functional
class (FC) II (n = 14; +80.7 m) and III (n = 55; +62.7 m).
Plasma NT-proBNP, dyspnea and FC also improved.
Conclusion
In summary, riociguat significantly improves pulmonary
hemodynamics and exercise capacity from baseline in
subjects with PAH or CTEPH and warrants further, con-
trolled clinical study.
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